Drug Approval | October 23, 2023
Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
The plant has a capacity for extraction of 2500 mt of poppy straw and 300 mt poppy gum per year
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Subscribe To Our Newsletter & Stay Updated
